Nanovibronix (NASDAQ:FEED) Upgraded by Wall Street Zen to Hold Rating

Nanovibronix (NASDAQ:FEED) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a report issued on Saturday.

Separately, Weiss Ratings started coverage on shares of Nanovibronix in a report on Tuesday, January 27th. They set a “sell (e+)” rating for the company. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Nanovibronix Price Performance

FEED opened at $2.75 on Friday. The company has a market capitalization of $3.00 million, a PE ratio of -0.07 and a beta of 2.21. Nanovibronix has a 1-year low of $0.99 and a 1-year high of $162.50.

Insider Activity

In related news, major shareholder Christian Michael Glibert bought 240,000 shares of the firm’s stock in a transaction on Wednesday, January 14th. The stock was bought at an average cost of $2.67 per share, for a total transaction of $640,800.00. Following the completion of the purchase, the insider directly owned 240,000 shares in the company, valued at approximately $640,800. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.40% of the company’s stock.

Nanovibronix Company Profile

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.